Health professional awareness of treatment-related bone loss in prostate cancer

Autor:	Simon M. Hughes, Peter Harper, S. Chowdhury, L. Drudge-Coates, Sophie Burbridge, Gordon Kooiman, Declan Cahill, Janette Kinsella, Kiruthikah Thillai, C. Tang, A. Garcia-Imhof, S. Rudman
Rok vydání:	2011
Předmět:	musculoskeletal diseases Oncology Bone mineral Cancer Research medicine.medical_specialty Health professionals business.industry Gold standard Cancer Disease medicine.disease Androgen deprivation therapy Prostate cancer Denosumab Internal medicine Physical therapy Medicine business medicine.drug
Zdroj:	Journal of Clinical Oncology. 29:e15099-e15099
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2011.29.15_suppl.e15099
Popis:	e15099 Background: Prostate cancer is the most common male cancer. Androgen deprivation therapy (ADT) is the mainstay of treatment for metastatic disease, and is increasingly used in radical therapy. Treatment with ADT causes bone mineral density (BMD) loss, and is a significant contributor to fracture risk. Therapy with bisphosphonates, raloxifen or denosumab can impact on BMD loss. Imaging with dual energy X-ray absorptiometry (DEXA) scanning is the gold standard for the quantification of BMD. Despite the growing body of evidence supporting BMD loss secondary to ADT a screening and management consensus has not been reached in the United Kingdom. Methods: A questionnaire based study was undertaken. The aims were to investigate current practice around bone health among health professionals treating men with ADT for prostate cancer. Results: Responses from 76 urologists, 49 clinical nurse specialists (CNS) and 48 medical oncologists (of which only 12 regularly treat prostate cancer) have been evaluated to ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::df1bc8d384fdef9abbb57d0203efb2c2 https://doi.org/10.1200/jco.2011.29.15_suppl.e15099 Zobrazit plný text záznamu